Wave Initiates Phase 2a WVE-007 Combination Trial for Obesity
CAMBRIDGE, Mass. — September 23, 2026 Wave Life Sciences announced the initiation of a Phase 2a clinical trial evaluating...
Weight loss
Advertisement
Artelo Files Patent for ART27.13 in Obesity
SOLANA BEACH, Calif. — September 23, 2026 Artelo Biosciences announced that it has filed a new provisional patent application...
Viking Therapeutics Reports Positive VK2735 Weight Results
San Diego, California, U.S., September 22, 2026 Viking Therapeutics, Inc. has announced positive topline results from a maintenance study...
MitoRx to Present MTRX31 Obesity Data at EASD 2026
HARWELL, Oxford, UK — September 17, 2026 MitoRx Therapeutics announced that new data for its lead mitochondrial-targeted small molecule...
Syntis Bio Advances Oral SYNT-101 Toward Phase 2
BOSTON — September 15, 2026 Syntis Bio, Inc. announced results from the 28-day multiple-ascending-dose (MAD) portion of its Phase...
Advertisements
Corbus Advances CRB-913 Toward Phase 2 in Obesity
NORWOOD, Mass. — September 14, 2026 Corbus Pharmaceuticals Holdings, Inc. announced positive topline results from its CANYON-1 Phase 1b...
Ascletis Starts Phase III Trial of Oral GLP-1 Drug
Hong Kong, China, August 30, 2026 Ascletis Pharma Inc. announced that the first participant has been dosed in its...
Biomea Fusion Doses First Patient in Obesity OPAL Study
SAN CARLOS, Calif., August 13, 2026 Biomea Fusion, Inc. announced that the first participant has been dosed in a...
Veru Advances PLATEAU Trial with Full Enrollment
Miami, Florida, August 10, 2026 Veru Inc. has announced full enrollment of 239 patients in its Phase 2b PLATEAU...
Verdiva Bio Starts Phase 1 Trial of Weekly Oral VRB-103
LONDON and SAN FRANCISCO, July 30, 2026 Verdiva Bio announced that the first patient has been dosed in a...
Advertisement
